Full Press Release Details
Hologic Announces Financial Results for
First Quarter Fiscal 2015
- Revenues Increase 6.6% to $652.8
- Company Records GAAP EPS of $0.10,
Non-GAAP EPS of $0.39 -
- Company Raises Full-Year Revenue
and Earnings Guidance -
Bedford, Mass. (January 28, 2015) - Hologic, Inc.
(NASDAQ: HOLX) announced today the Company's financial results for the first fiscal quarter ended December 27, 2014.
Revenues for the quarter were $652.8 million, an increase of
6.6% compared to the prior year period. On a constant currency basis, revenues increased 7.7%. Revenues grew in all four business
| $s in millions | Total Revenues | Change (As Reported) | Change (Constant Currency) |
| Diagnostics | $304.1 | 6.4% | 7.4% |
| Breast Health | $242.0 | 6.9% | 8.2% |
| GYN Surgical | $84.4 | 7.0% | 7.9% |
| Skeletal Health | $22.3 | 4.5% | 6.1% |
| Total | $652.8 | 6.6% | 7.7% |
GAAP net income was $29.2 million in the quarter, compared to
a net loss of ($5.3 million) in the prior year period. Non-GAAP net income of $111.6 million increased by 18.6% and represented
17.1% of revenues, compared to 15.4% of revenues in the prior year period.
GAAP earnings per share (EPS) were $0.10 on a fully diluted
basis in the quarter, compared to a net loss per diluted share of ($0.02) in the prior year period. Non-GAAP EPS were $0.39 on
a fully diluted basis in the quarter, an increase of 15.4% compared to the prior year period.
"We posted strong organic revenue and earnings growth
across the board in the first quarter," said Steve MacMillan, Hologic's President and Chief Executive Officer. "We
are pleased with the pace of progress we have made, as we recorded our fourth consecutive quarter of sequential revenue growth,
and our best quarterly growth rate in a number of years. While we realize there is still work to do, this quarter's results
show that great products, great people, and new leadership are coming together in a powerful way at the Company. As a result, we
are raising our financial outlook for the year."
In this section, all revenues are on a reported basis for the
first quarter of fiscal 2015, and are compared to the prior year period.
Diagnostics revenues of $304.1 million increased 6.4%. This
increase was driven by a 26.3% increase in blood screening revenue from our partner Grifols, mainly from new business with the
Japanese Red Cross, and by a 5.6% increase in molecular diagnostics revenue, mainly from the Aptima product line. Revenue
from cytology and perinatal products declined by 1.2%, a lower rate of decline than in recent quarters.
Breast Health revenues of $242.0 million grew 6.9%. This increase
was primarily driven by a 10.9% increase in breast imaging and service revenue, as customers continued to adopt Hologic 3D mammographyTM,
while interventional breast revenue declined 2.3%.
GYN Surgical revenues of $84.4 million grew 7.0%, driven by
a 27.4% increase in MyoSure system sales. NovaSure system sales also increased 0.1% in the quarter, an improvement compared to
the declines seen in recent quarters.
Skeletal Health revenues of $22.3 million grew 4.5%, primarily
driven by increased sales of the Company's new HorizonTM bone densitometry system.
Balance Sheet and Cash Flows
Hologic continues to focus on reducing its debt. Total debt
outstanding at quarter-end was $3,954.8 million, a $312.9 million decrease from the end of fiscal 2014 that resulted primarily
from a $300 million voluntary pre-payment of the Term Loan B facility in December. The Company ended the first fiscal quarter with
cash and equivalents of $549.1 million.
Adjusted non-GAAP earnings before interest, taxes, depreciation
and amortization (EBITDA) were $233.1 million in the quarter. Operating cash flow was $153.5 million, while free cash flow, defined
as operating cash flow less capital expenditures, was $132.4 million.
Updated Financial Guidance
Based on the Company's strong performance in the first
quarter of fiscal 2015, Hologic is raising its full year 2015 revenue and non-GAAP EPS guidance, as shown in the table below. The
guidance for reported results is based on recent foreign exchange rates. Percentage changes from the prior year exclude one-time
benefits associated with the restructuring of the Roka license, which totaled $20.1 million of revenue and $0.05 of EPS in 2014.
| Initial Guidance From 11/5/14 | Updated Guidance | Change vs. Prior Year (As Reported) | Change vs. Prior Year (Constant Currency) | |
| Revenues | $2.54 to $2.57 billion | $2.57 to $2.60 billion | 2.4% to 3.6% | 4.4% to 5.6% |
| Non-GAAP EPS | $1.50 to $1.54 | $1.54 to $1.57 | 5.5% to 7.5% | 8.9% to 11.0% |
Since the Company provided its initial financial guidance on
November 5, 2014, the US dollar has strengthened significantly. If the US dollar were at the same level today as it was in early
November, the Company's updated revenue guidance would have been approximately $25 million higher, and its updated EPS guidance
would have been approximately $0.02 higher.
For the second quarter of fiscal 2015, the Company now expects:
| Guidance | Change vs. Prior Year Period (As Reported) | Change vs. Prior Year Period (Constant Currency) | |
| Revenues | $640 to $650 million | 2.4% to 4.0% | 4.5% to 6.1% |
| Non-GAAP EPS | $0.38 to $0.39 | 2.7% to 5.4% | 5.5% to 8.0% |
Use of Non-GAAP Financial Measures
The Company has presented the following non-GAAP financial measures
in this press release: constant currency revenues; net income; EPS; and adjusted EBITDA. The Company defines adjusted EBITDA as
its non-GAAP net income plus net interest expense, income taxes, and depreciation and amortization expense included in its non-GAAP
net income. The Company defines its non-GAAP net income and EPS to exclude: (i) the amortization of intangible assets and impairment
of goodwill and intangible assets; (ii) acquisition-related charges and effects, such as charges for contingent consideration,
transaction costs, integration costs including retention, and credits and/or charges associated with the write-up of acquired inventory
and fixed assets to fair value; (iii) non-cash interest expense related to amortization of the debt discount from the equity conversion
option of the convertible debt securities; (iv) restructuring and divestiture charges; (v) debt extinguishment losses and related
transaction costs; (vi) litigation settlement charges (benefits); (vii) other-than-temporary impairment losses on investments;
(viii) other one-time, nonrecurring, unusual or infrequent charges, expenses or gains that may not be indicative of the Company's
core business results; and (ix) income taxes related to such adjustments.
The Company believes the use of non-GAAP financial measures
is useful to investors by eliminating certain of the more significant effects of its acquisitions and related activities, non-cash
charges resulting from the application of GAAP to convertible debt instruments with cash settlement features, charges related to
debt extinguishment losses, investment impairments, litigation settlements, and restructuring and divestiture initiatives. These
non-GAAP measures also reflect how Hologic manages its businesses internally. In addition to the adjustments set forth in the calculation
of the Company's non-GAAP net income and EPS, its adjusted EBITDA eliminates the effects of financing, income taxes and the
accounting effects of capital spending. As with the items eliminated in its calculation of non-GAAP net income, these items may
vary for different companies for reasons unrelated to the overall operating performance of a company's business. When analyzing
the Company's operating performance, investors should not consider these non-GAAP financial measures as a substitute for
net income prepared in accordance with GAAP.
Future Non-GAAP Adjustments
Future GAAP EPS may be affected by changes in ongoing assumptions
and judgments relating to the Company's acquired businesses, and may also be affected by nonrecurring, unusual or unanticipated
charges, expenses or gains, which are excluded in the calculation of the Company's non-GAAP EPS guidance as described in
this press release. It is therefore not practicable to reconcile non-GAAP EPS guidance to the most comparable GAAP measure.
Conference Call and Webcast
Hologic's management will host a conference call at 4:30
p.m. ET today to discuss its first quarter fiscal 2015 operating results. Approximately 10 minutes before the call, dial 877-675-4750
(US and Canada) or 719-325-4801 (international) and enter access code 9937337. A replay will be available starting two hours after
the call ends through February 18, 2015, at 888-203-1112 or 719-457-0820 for international callers, access code 9937337. The Company
will also provide a live webcast of the call at www.investors.hologic.com/investors-overview. A PowerPoint presentation related
to the conference call will be posted to the same site.
Hologic, Inc. is a leading developer, manufacturer and supplier
of premium diagnostic products, medical imaging systems and surgical products. The Company's core business units focus on
diagnostics, breast health, GYN surgical, and skeletal health. With a unified suite of technologies and a robust research
and development program, Hologic is dedicated to The Science of Sure. For more information on Hologic, visit www.hologic.com.
Hologic, Aptima, Horizon, MyoSure, NovaSure, The Science of
Sure, ThinPrep and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the
United States and/or other countries.
Forward-Looking Statements